English Community

If you or someone you know has taken the drug ELAHERE (mirvetuximab-soravtansine) and are interested in taking part in a 20-minute interview with OCC staff so that your experience with this treatment can be considered in the drug approval process in Canada, please contact Alexandria Tadman, atadman@ovariancanada.org by December 5, 2024.

Thanks!

My mom fought hard against this disease and made every effort to access promising treatments. She even traveled to the U.S. to consult with a doctor, but unfortunately, it didn’t lead to the results we hoped for. Elahere has a 35% response rate for platinum-resistant patients—significantly higher than the 10% response rate of most third-tier drugs currently available.

This difference in efficacy is staggering and could mean the world to so many families battling ovarian cancer. Patients shouldn’t have to face insurmountable barriers to access potentially life-saving treatments. I sincerely hope this drug is approved soon so others won’t have to go through the same struggles my mom faced.

Thank you for considering this important issue.

@mymomisawarrior thank you for sharing your comments here. If you'd be willing to have a conversation about your mom's experience, please reach out to Alexandria (atadman@ovariancanada.org), she would appreciate your input.

@mfallis she never took the drug as it wasn’t available to her. I can certainly speak on the struggle to access it.